ICPT News Alert Intercept Pharmaceuticals Inc (ICPT) 151.49 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Intercept Pharmaceuticals Inc (ICPT) 151.49 $ICPT

The 2015 Calendar Of NASH Trial Catalysts III: Galmed And Intercept
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 11:23AM CST

GLMD: 5.95 (+0.15), ICPT: 151.49 (+5.85)

Critical Alerts For GoPro, Aeropostale, Magna International, Cliffs Natural Resources and Intercept Pharmaceuticals Released By InvestorsObserver
PR Newswire - Thu Dec 18, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for GPRO, ARO, MGA, CLF and ICPT.
GPRO: 66.41 (+4.87), ICPT: 151.49 (+5.85), MGA: 107.93 (+0.35), CLF: 6.06 (-0.09), ARO: 2.30 (-0.03)

Liver Fibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/wmnbdp/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Fibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Genzyme - Gilead Sciences - Bioneer - FibroGen - Silence Therapeutics - Celgene - Nitto Denko - Genfit - Pharmaxis - La Jolla Pharmaceutical - ProMetic Life Sciences - LG Life Sciences - Digna Biotech - Advinus Therapeutics - Promedior - GenKyoTex - Angion Biomedica - Virobay - Intercept Pharmaceuticals - Tobira Therapeutics - GNI Group - Promethera Biosciences - BiOrion Technologies - ACROVIS biostructures - RXi Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/wm...r_fibrosis
GILD: 91.29 (+1.84), ICPT: 151.49 (+5.85), TBRA: (), CELGZ: 3.34 (-0.01)

Insider Trading Alert - ICPT, BOFI And JGW Traded By Insiders
at The Street - Tue Dec 16, 2:07PM CST
Stocks with insider trader activity include ICPT, BOFI and JGW
BOFI: 79.32 (+0.32), ICPT: 151.49 (+5.85), JGW: 10.70 (+0.04)

Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 88.76 (+3.23), BMRN: 88.18 (+0.89), TGTX: 16.03 (+0.33), BMY: 59.15 (-0.01), MACK: 10.91 (+0.36), FMI: 23.99 (-0.10), RNA: 18.76 (+0.10), GWPH: 68.08 (+1.82), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), ICPT: 151.49 (+5.85), THLD: 2.93 (+0.01), CEMP: 20.66 (+0.78), NVS: 93.91 (+0.66)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Intercept Announces Publication of Meta-Analysis From the Global PBC Study Group in Gastroenterology
GlobeNewswire - Fri Dec 05, 5:25AM CST
- Largest Analysis of Data from Patients with Primary Biliary Cirrhosis
ICPT: 151.49 (+5.85)

How to Make Money in Biotech Stocks
Diana Gordon - Daily Reckoning - Wed Dec 03, 4:25PM CST
This post How to Make Money in Biotech Stocks appeared first on Daily Reckoning . Biotech stocks delivered triple-digit returns throughout the ’80s and ’90s. But it’s been a decade since we’ve seen similar results. Investment director Paul...
ICPT: 151.49 (+5.85), PBYI: 189.96 (+0.12)

Why Intercept Pharmaceuticals Inc. Stock Was Throttled in November
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 01, 3:37PM CST
ICPT data by YCharts What: Shares of Intercept Pharmaceuticals , a clinical-stage biopharmaceutical company aiming to develop drugs to treat chronic liver disease, were absolutely throttled in November, losing 44% of their value based on...
ICPT: 151.49 (+5.85)

3 Biotech Stocks With Jaw-Dropping Growth Potential in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Nov 29, 1:01PM CST
The biotech industry has been absolutely soaring over the past two years, fueled by a rise in drug approvals, an merger-and-acquisition frenzy, and widespread reorganizations that have helped to mitigate the impact of the so-called "patent cliff."...
JNJ: 104.59 (+0.31), FLML: 17.01 (-0.98), GERN: 3.06 (+0.05), ICPT: 151.49 (+5.85), IBB: 299.80 (+5.12)

Why Intercept Pharmaceuticals (ICPT) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 7:40AM CST
Intercept Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative earnings estimate revisions for the current quarter and the current year, making it time for investors to sell it off
HSKA: 18.13 (+0.24), ICPT: 151.49 (+5.85), AMAG: 43.02 (+0.90), DYAX: 14.13 (+0.30)

Intercept to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Nov 25, 5:04AM CST
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced management will be participating in the following upcoming investor conferences:
ICPT: 151.49 (+5.85), DB: 30.95 (+0.04)

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Tue Nov 25, 2:06AM CST

CXO: 99.86 (-0.04), CAM: 50.11 (-0.19), MDLZ: 37.63 (+0.05), MON: 120.97 (-1.70), DAL: 48.05 (+0.92), KSU: 122.50 (-0.80), CFX: 52.40 (-0.35), KORS: 75.30 (-0.01), RL: 184.35 (+0.70), PCP: 241.29 (+0.29), GOOG: 528.77 (-1.82), MOH: 53.39 (+0.61), PBR: 7.60 (-0.11), HLT: 26.21 (+0.11), DLTR: 69.86 (-0.20), LYB: 81.31 (-0.89), COF: 83.23 (-0.05), FOXA: 38.71 (-0.03), ABBV: 66.21 (+1.86), LOW: 67.51 (-0.43), REGN: 400.12 (+6.07), MA: 87.77 (+0.14), MU: 34.91 (-0.06), FB: 80.77 (+0.16), LNG: 71.64 (-0.12), NFX: 27.86 (-0.39), PXD: 150.84 (-1.60), ALXN: 181.96 (+3.09), ICPT: 151.49 (+5.85), CTSH: 54.26 (+0.04), ADSK: 60.99 (+0.34), DHI: 24.80 (-0.01), CCI: 79.05 (-0.13), ACT: 254.20 (-1.68), LBTYK: 49.10 (+0.05), MDT: 74.08 (+0.31), C: 54.54 (+0.12), ILMN: 186.22 (+2.72), AON: 96.52 (-0.15), ADBE: 74.74 (+0.36), MMC: 58.32 (-0.07), HUM: 144.38 (-0.31), AGN: 210.12 (+0.95), ACAD: 30.95 (+0.78), LBTYA: 50.76 (-0.02), GOOGL: 536.93 (-1.84), AAPL: 112.01 (-0.53), APD: 148.58 (unch), HRB: 33.72 (-0.08), GLNG: 36.67 (+1.15), BAC: 17.98 (+0.05), NFLX: 342.10 (+5.67), HCA: 74.89 (-0.11), BIDU: 230.98 (-2.18), DVA: 76.06 (+0.07), KITE: 51.96 (+0.45), MHK: 154.56 (-0.21), CP: 194.85 (-0.13), BABA: 105.95 (+0.43)

Critical Alerts For JA Solar, 2U, AT&T, Mobileye NV and Intercept Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Nov 19, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for JASO, TWOU, T, MBLY and ICPT.
T: 33.96 (-0.07), JASO: 8.03 (+0.13), ICPT: 151.49 (+5.85), TWOU: 19.44 (-0.18), MBLY: 44.00 (+0.05)

Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 254.20 (-1.68), QLTI: 3.72 (+0.08), VRX: 140.33 (-0.22), AGN: 210.12 (+0.95), SHPG: 209.29 (+0.07), AUXL: 34.40 (+0.18), ABBV: 66.21 (+1.86), SNY: 46.35 (+0.50), ABT: 45.70 (-0.02), ENDP: 72.10 (+0.34), AKRX: 36.47 (+0.43), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), SLXP: 114.92 (-1.18), MYL: 56.97 (+0.39), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), ACHN: 13.06 (+1.22), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), ICPT: 151.49 (+5.85), TEVA: 57.09 (+0.33), NVS: 93.91 (+0.66)

Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 254.20 (-1.68), QLTI: 3.72 (+0.08), VRX: 140.33 (-0.22), AGN: 210.12 (+0.95), SHPG: 209.29 (+0.07), AUXL: 34.40 (+0.18), ABBV: 66.21 (+1.86), SNY: 46.35 (+0.50), ABT: 45.70 (-0.02), ENDP: 72.10 (+0.34), AKRX: 36.47 (+0.43), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), SLXP: 114.92 (-1.18), MYL: 56.97 (+0.39), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), ACHN: 13.06 (+1.22), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), ICPT: 151.49 (+5.85), TEVA: 57.09 (+0.33), NVS: 93.91 (+0.66)

Intercept Pharmaceuticals hires Lisa Bright as head of Europe
M2 - Tue Nov 18, 6:30AM CST
Biopharmaceutical company Intercept Pharmaceuticals (NasdaqGS:ICPT) revealed on Monday the election of Lisa Bright as senior vice president and head of Europe.
ICPT: 151.49 (+5.85)

Intercept Pharmaceuticals names Lisa Bright as senior vice president and head of Europe
M2 - Mon Nov 17, 6:48AM CST
Biopharmaceutical company Intercept Pharmaceuticals (NasdaqGS:ICPT) has appointed Lisa Bright as senior vice president and head of Europe, it revealed on Friday.
ICPT: 151.49 (+5.85)

Intercept Pharmaceuticals Appoints Lisa Bright as Head of Europe
GlobeNewswire - Mon Nov 17, 5:01AM CST
Intercept Pharmaceuticals (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases, announced today the appointment of Lisa Bright as Senior Vice President and Head of Europe, effective November 17, 2014. Ms. Bright will be a member of the Intercept senior management team and will spearhead Intercept's European operations based in London as the company prepares for the first indication approval and launch of obeticholic acid (OCA).
GILD: 91.29 (+1.84), ICPT: 151.49 (+5.85)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 108

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 101

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 103

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 29

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 76

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 118

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 99

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 73

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 62

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading

Top 5 Most Recently Viewed Articles

Redsun Properties Faces $350 Million Bond Payment Crisis Ahead

Updated Category News Views 189

Redsun Properties Announces Inability to Pay Bond Chinese property developer Redsun Properties has communicated its inability to meet a $350 million bond payment, which is due shortly. This situation has raised considerable concern within the financial markets as it highlights the ongoing issues facing property developers in China. Details of the Bond Issue This bond,...

Continue Reading
Etruscus Resources Unveils Promising Findings at Zappa Target

Updated Category News Views 135

Etruscus Resources Makes Progress at Key Exploration Sites Etruscus Resources Corp. is thrilled to report on the encouraging findings from its exploration program at the Rock & Roll Property. This property is situated in the Golden Triangle region, known for its wealth of mineral resources. The exploration program, which included comprehensive rock sampling and geological...

Continue Reading
MetLife's Strategic Focus: Navigating Q3 2024 Earnings

Updated Category News Views 1091

MetLife Announces Q3 2024 Results and New Frontier Strategy In the third quarter of 2024, MetLife, Inc. (MET) reported adjusted earnings of $1.4 billion, translating to $1.93 per share. This reflects a decline from previous year figures, yet a 12% year-to-date increase in adjusted earnings per share (EPS) excluding notable items. The insurance powerhouse has seen positive...

Continue Reading
VEON Invests in Ukraine: Commitment to Digital Growth

Updated Category News Views 125

VEON's Commitment to Investing in Ukraine VEON Ltd. (NASDAQ: VEON), a leading global digital operator, has recently made significant news with its promise to enhance Ukraine’s telecommunications infrastructure. In collaboration with its fully-owned subsidiary, Kyivstar, VEON participated in the 2024 Yalta European Strategy (YES) Annual Meeting. At this event, the focus...

Continue Reading
Expanding Diabetes Care: From Monitoring to Change

Updated Category News Views 44

Breaking Ground at the AGP & DTx Summit Diabetes management ain't what it used to be, and the 4th AGP & DTx Summit in Shenzhen gave us an eyeful of change. Under the banner "Beyond Glucose," experts from all corners came together to talk shop about Continuous Glucose Monitoring (CGM) and how it might shake up diabetes care. CGM: More Than a Gadget See, CGM's not just a...

Continue Reading